Immix Biopharma (IMMX) Net Equity Issued and Repurchased (2022 - 2025)

Immix Biopharma has reported Net Equity Issued and Repurchased for 4 years, with the latest figure at $95.5 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $95.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $106.3 million (up 566.55% YoY) and the FY2025 annual result came in at $107.4 million, up 573.47% from the prior year.
• Net Equity Issued and Repurchased grew to $95.5 million in Q4 2025 per IMMX's latest filing, from $10.8 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $95.5 million in Q4 2025 and troughed at -$2.4 million in Q4 2022.
• A 4-year average of $15.4 million and a median of $4.7 million in 2023 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased slumped 96.43% in 2023, then soared 15245.16% in 2024.
• Over 4 years, Net Equity Issued and Repurchased stood at -$2.4 million in 2022, then soared by 123.95% to $584073.0 in 2023, then soared by 2630.15% to $15.9 million in 2024, then surged by 498.98% to $95.5 million in 2025.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $95.5 million, $10.8 million, and $15.9 million for Q4 2025, Q3 2025, and Q1 2024 respectively.